_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Over 70 per cent of the world’s population have no access to MRI scanners and the situation is not that encouraging in India where there are only 0.4 MRI scanners per thousand people
HTL will build, validate and operate a botulinum manufacturing facility in the US
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
The panel is headed by DCGI Dr VG Somani with representatives from various state drug regulators and health ministry
The medicine is now approved for eight indications across five different types of cancer in China.
Subscribe To Our Newsletter & Stay Updated
